SG190449A1 - Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients - Google Patents

Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients Download PDF

Info

Publication number
SG190449A1
SG190449A1 SG2013042403A SG2013042403A SG190449A1 SG 190449 A1 SG190449 A1 SG 190449A1 SG 2013042403 A SG2013042403 A SG 2013042403A SG 2013042403 A SG2013042403 A SG 2013042403A SG 190449 A1 SG190449 A1 SG 190449A1
Authority
SG
Singapore
Prior art keywords
improving
laquinimod
life
multiple sclerosis
functional status
Prior art date
Application number
SG2013042403A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG190449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG190449A1 publication Critical patent/SG190449A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013042403A 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients SG190449A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
SG190449A1 true SG190449A1 (en) 2013-07-31

Family

ID=46162796

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013042403A SG190449A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
SG10201509831XA SG10201509831XA (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201509831XA SG10201509831XA (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Country Status (19)

Country Link
US (1) US20120142730A1 (enExample)
EP (1) EP2648732A4 (enExample)
JP (2) JP2013544887A (enExample)
KR (1) KR20130124518A (enExample)
CN (1) CN103260624B (enExample)
AU (2) AU2011338647A1 (enExample)
BR (1) BR112013014061A2 (enExample)
CA (1) CA2820586A1 (enExample)
CL (1) CL2013001602A1 (enExample)
EA (1) EA201390827A1 (enExample)
IL (1) IL250726A0 (enExample)
MX (1) MX2013006464A (enExample)
NZ (1) NZ611628A (enExample)
PE (1) PE20140872A1 (enExample)
PH (1) PH12013501193A1 (enExample)
SG (2) SG190449A1 (enExample)
UA (1) UA111959C2 (enExample)
WO (1) WO2012078591A1 (enExample)
ZA (1) ZA201304237B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107176923A (zh) * 2005-10-19 2017-09-19 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
ES2731052T3 (es) 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
WO2011109531A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
KR20150135552A (ko) * 2010-03-03 2015-12-02 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
JP2013535437A (ja) 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
IN2015DN03219A (enExample) * 2012-09-27 2015-10-02 Teva Pharma
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington
WO2015109083A1 (en) * 2014-01-17 2015-07-23 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease using low doses of laquinimod
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
JP6731915B2 (ja) * 2014-10-16 2020-07-29 ノバルティス アーゲー 多発性硬化症治療用のシポニモドとラキニモドを含む組み合わせ
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
ES2973119T3 (es) * 2018-10-09 2024-06-18 Medicinova Inc Combinación de ibudilast e interferón-beta y métodos de uso
CA3145269A1 (en) * 2019-07-22 2021-01-28 Michel BURCKLEN Use of ponesimod for the treatment of multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1797109T3 (pl) * 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR101495327B1 (ko) * 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
PT2137537E (pt) * 2007-02-08 2013-08-22 Biogen Idec Inc Composições e respectivas utilizações para o tratamento da esclerose múltipla
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod

Also Published As

Publication number Publication date
CN103260624B (zh) 2015-06-03
WO2012078591A8 (en) 2012-08-02
MX2013006464A (es) 2013-07-29
NZ611628A (en) 2015-06-26
CN103260624A (zh) 2013-08-21
AU2011338647A1 (en) 2013-07-04
UA111959C2 (uk) 2016-07-11
JP2017095476A (ja) 2017-06-01
PH12013501193A1 (en) 2013-07-15
ZA201304237B (en) 2014-08-27
EP2648732A1 (en) 2013-10-16
BR112013014061A2 (pt) 2016-09-13
EP2648732A4 (en) 2014-04-30
CA2820586A1 (en) 2012-06-14
WO2012078591A1 (en) 2012-06-14
SG10201509831XA (en) 2015-12-30
EA201390827A1 (ru) 2013-12-30
CL2013001602A1 (es) 2013-10-25
KR20130124518A (ko) 2013-11-14
AU2017202055A1 (en) 2017-04-20
PE20140872A1 (es) 2014-08-09
US20120142730A1 (en) 2012-06-07
JP2013544887A (ja) 2013-12-19
IL250726A0 (en) 2017-04-30
AU2011338647A8 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
IL250726A0 (en) Use of lequinimod to reduce fatigue, improve function and improve quality of life in multiple sclerosis patients
IL252699A0 (en) Use of lequinimod to treat multiple sclerosis
ZA201403378B (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
GB2481911B (en) Hard face structure, body comprising same and method for making same
EP2686514B8 (en) Integral wear pad and method
PL2685994T3 (pl) Bakterie probiotyczne wykazujące aktywność przeciwutleniającą i ich zastosowanie
ZA201401217B (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
EP2716669A4 (en) METHOD OF MODIFYING SURFACE AND ELASTIC BODY HAVING MODIFIED SURFACE
SG11201401949YA (en) Nadph oxidase 4 inhibitors and use thereof
EP2790709A4 (en) HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF
EP2731601A4 (en) EOSINOPHILIC PEROXIDASE COMPOSITIONS AND METHOD FOR THEIR USE
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
GB0920258D0 (en) New medical agents and use thereof
IL232174A0 (en) Preparations containing a salt of a sodium channel inhibitor and their uses
LT2696871T (lt) Aklidinas, skirtas naudoti miego kokybės pagerinimui kvėpavimo problemų turintiems pacientams
PT2790706T (pt) Fitoecdisonas para utilização na melhoria da qualidade muscular de mamíferos obesos e sarcopénicos
HK1188950A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2781227A4 (en) ELEMENT FOR USE IN A TEXTILE GENERATION, MANUFACTURING METHOD AND INK
HK1193751A (en) Aclidinium for use in improving the quality of sleep in respiratory patients
EG27140A (en) Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
IL215573A0 (en) Scouring sponge with symbol of " meet" , " milk" and " parve"
TWM402465U (en) Mouse pad for use in wheelchair